NDLI: Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

Please wait, while we are loading the content...

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.

Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.

Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study.

Comparison of lidocaine, metoclopramide, and flurbiprofen axetil for reducing pain on injection of propofol in Japanese adult surgical patients: a prospective, randomized, double-blind, parallel-group, placebo-controlled study.

A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients.

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Observations of nonadherence to recombinant human growth hormone therapy in clinical practice.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.

An invitation to the health policy debates.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

Patterns of treatment for restless legs syndrome in primary care in the United Kingdom.

Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or =77 years in Sweden.

Year: 2008 Volume: 30 Issue: 1

Year: 2008 Volume: 30 Issue: Supplementary C

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Reilly, Margaret C. Gerlier, Laetitia Brabant, Yves Brown, Martin
Description	Country affiliation: United States Author Affiliation: Reilly MC ( Margaret Reilly Associates, New York, New York, USA.)
Abstract	BACKGROUND: Crohn's disease (CD) is a chronic inflammatory bowel disease usually diagnosed in early adult life and characterized by unpredictable flares and debilitating symptoms such as diarrhea, abdominal pain, and fever, which can interfere with a patient's ability to work and perform daily activities. OBJECTIVE: The aim of this study was to assess the validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in CD (WPAI:CD). METHODS: The WPAI:CD was tested in CD patients enrolled in a 26-week randomized clinical trial of cer-tolizumab pegol versus placebo. Discriminative validity of WPAI:CD absenteeism, presenteeism(reduced on-the-job effectiveness), overall work productivity loss (absenteeism + presenteeism), and activity impairment scores was assessed relative to 5 measures of disease severity and health status: CD Activity Index (CDAI), Short Form-36 physical component summary (PCS) and mental health component summary (MCS) scores, Inflammatory Bowel Disease Questionnaire (IBDQ), and the 5-dimensional EuroQoL health-related quality-of-life visual analog scale (EQ-VAS). Responsiveness was assessed by comparing changes in WPAI:CD scores from baseline to week 26 for patients in remission (CDAI <150 points) versus no remission. Standardized Response Means (SRMs) were calculated to evaluate the magnitude of the changes. RESULTS: A total of 662 patients (mean [range] age, 37.4 [18-77] years; male, 288 [43.5%]; white, 629 [95.0%]) were enrolled in the study. Patients with CD of the worst severity (CDAI > median) showed significantly higher impairment in work (+10.5%) and activities (+10.4%) versus patients with 'best health' (no problems) (both, P < or = 0.001). Patients with 'worst' IBDQ, PCS, MCS, and EQ-VAS scores also showed significantly higher impairments in work (IBDQ, VAS -24.2%; PCS, -24.1%; MCS, -15.9%; EQ-VAS, -16.5%) and activities (IBDQ, -23.3%; PCS, -21.8%; MCS, -16.5%; EQ-VAS, -17.2%) versus 'best' scores (all, P < 0.05). There were significant differences between WPAI:CD impairment scores for patients in remission versus patients failing to achieve remission (P < 0.05). SRMs were small (ie, <0.5) in the nonre-mission group, and moderate to large (ie, >0.5) for patients in remission. CONCLUSIONS: The discriminative validity, reliability, and responsiveness of the WPAI:CD were demonstrated. The WPAI:CD may be useful for evaluating drug impact on CD.
File Format	HTM / HTML
ISSN	01492918
Issue Number	2
Volume Number	30
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2008-02-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Absenteeism Activities Of Daily Living Cost Of Illness Crohn Disease Diagnosis Sick Leave Questionnaires Adolescent Adult Aged Antibodies, Monoclonal, Humanized Certolizumab Pegol Drug Therapy Physiopathology Psychology Female Gastrointestinal Agents Therapeutic Use Humans Immunoglobulin Fab Fragments Male Middle Aged Polyethylene Glycols Predictive Value Of Tests Quality Of Life Reproducibility Of Results Severity Of Illness Index Time Factors Treatment Outcome Young Adult Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-u.s. Gov't Validation Studies
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Drug approvals: '08 in review. Certolizumab pegol (Cimzia).

Certolizumab pegol in Crohn's disease.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.

Certolizumab pegol.

Drug safety evaluation of certolizumab pegol.

Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.

TNF-alpha-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben.

Safety considerations when using anti-TNF therapy to treat Crohn's disease.

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

Similar Documents

Drug approvals: '08 in review. Certolizumab pegol (Cimzia).

Certolizumab pegol in Crohn's disease.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.

Certolizumab pegol.

Drug safety evaluation of certolizumab pegol.

Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.

TNF-alpha-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben.

Safety considerations when using anti-TNF therapy to treat Crohn's disease.

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.